Frank M. Ruemmele

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Disease
• Cancer

His primary scientific interests are in Inflammatory bowel disease, Internal medicine, Disease, Crohn's disease and Gastroenterology. The concepts of his Inflammatory bowel disease study are interwoven with issues in Paracrine signalling, Immunology, Ulcerative colitis, Caspase and Western blot. In his study, which falls under the umbrella issue of Disease, Evidence-based practice is strongly linked to Surgery.

His research in Crohn's disease focuses on subjects like Infliximab, which are connected to Gastrointestinal agent, Thiopurine methyltransferase, Hemophagocytic lymphohistiocytosis and Malignancy. His study in Gastroenterology is interdisciplinary in nature, drawing from both Guideline, Age of onset, Parenteral nutrition, Endoscopy and Bowel imaging. His biological study spans a wide range of topics, including Adalimumab, Primary sclerosing cholangitis and Intensive care medicine.

His most cited work include:

• Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. (832 citations)
• ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents (603 citations)
• Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. (562 citations)

What are the main themes of his work throughout his whole career to date?

Frank M. Ruemmele mostly deals with Internal medicine, Inflammatory bowel disease, Gastroenterology, Immunology and Crohn's disease. Frank M. Ruemmele frequently studies issues relating to Surgery and Internal medicine. His work carried out in the field of Inflammatory bowel disease brings together such families of science as Tumor necrosis factor alpha, Colitis, Intensive care medicine, Ulcerative colitis and Primary sclerosing cholangitis.

Frank M. Ruemmele has researched Immunology in several fields, including Autoimmune enteropathy and Age of onset. His Crohn's disease research is under the purview of Disease. His Disease study integrates concerns from other disciplines, such as Retrospective cohort study and Cohort.

He most often published in these fields:

• Internal medicine (54.87%)
• Inflammatory bowel disease (43.51%)
• Gastroenterology (36.36%)

What were the highlights of his more recent work (between 2018-2021)?

• Internal medicine (54.87%)
• Inflammatory bowel disease (43.51%)
• Crohn's disease (33.44%)

In recent papers he was focusing on the following fields of study:

Frank M. Ruemmele spends much of his time researching Internal medicine, Inflammatory bowel disease, Crohn's disease, Disease and Gastroenterology. His work on Adverse effect, Ulcerative colitis and Adalimumab as part of his general Internal medicine study is frequently connected to Pandemic and Severe acute respiratory syndrome coronavirus 2, thereby bridging the divide between different branches of science. His Inflammatory bowel disease research integrates issues from Tumor necrosis factor alpha, Immunology, Incidence and Increased risk.

In his work, Infliximab, Enteropathy, Progressive familial intrahepatic cholestasis and Phenotype is strongly intertwined with Parenteral nutrition, which is a subfield of Crohn's disease. His Disease study incorporates themes from Haploinsufficiency, Computational biology, Cohort and Intensive care medicine. His work in the fields of Erythrocyte sedimentation rate overlaps with other areas such as Chloride.

Between 2018 and 2021, his most popular works were:

• Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. (211 citations)
• Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition. (63 citations)
• The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. (20 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Cancer
• Disease

Crohn's disease, Internal medicine, Intensive care medicine, Clinical trial and Parenteral nutrition are his primary areas of study. Crohn's disease is a subfield of Disease that he studies. In the subject of general Disease, his work in Faecal calprotectin, Infliximab and Inflammatory bowel disease is often linked to Maintenance therapy, thereby combining diverse domains of study.

His studies in Inflammatory bowel disease integrate themes in fields like Intestinal dysbiosis, Granulomatous disease, Erythrocyte sedimentation rate and Receiver operating characteristic. In general Internal medicine, his work in Hepatology and Intensive care unit is often linked to Pandemic and Severe acute respiratory syndrome coronavirus 2 linking many areas of study. His Intensive care medicine research focuses on subjects like Position paper, which are linked to Dosing, Placebo and Clinical research.